Public Plans Should Cover Generic GLP-1s, Expert Says

Expert Weighs in on Public Coverage

Dr. Sanjeev Sockalingam has stated that public health plans should consider covering generic versions of semaglutide, the active ingredient in Ozempic and Wegovy, when multiple generic versions become available by the end of 2026. This recommendation comes as Health Canada continues reviewing nine applications for generic semaglutide products.

The expert's position addresses a key policy question facing provincial health systems as generic competition is expected to drive down medication costs significantly. Current brand-name semaglutide products can cost over $300 monthly without insurance coverage.

Current Generic Review Status

Health Canada is currently processing submissions from multiple pharmaceutical companies seeking approval to manufacture generic semaglutide. The generic semaglutide tracker shows applications from established manufacturers including:

• Sandoz Canada
• Apotex
• Teva Canada
• Taro Pharmaceuticals
• Aspen Pharmacare

Health Canada's standard review timeline for generic drug applications is 180 days, though this can extend if additional data is requested. The regulatory agency has indicated that the first generic approvals could come as early as mid-2026.

Coverage Policy Implications

The expert's recommendation highlights the potential for improved medication access through public insurance programs. Currently, many Canadians rely on private employer plans or pay out-of-pocket for brand-name semaglutide medications.

Provincial health plans typically reassess coverage criteria when generic versions become available, often expanding access due to lower costs. Generic medications typically cost 30-80% less than their brand-name counterparts once competition begins.

The recommendation comes as Canadian employers and insurers prepare for significant changes to drug plan costs and utilization patterns. Benefits consultants estimate that generic competition could reduce plan spending on semaglutide medications by up to 65%.

Manufacturing and Supply Considerations

Several companies are preparing Canadian manufacturing capabilities for generic semaglutide production. Vimy Pharma has announced plans to file its Health Canada application in the coming weeks, emphasizing domestic production capabilities.

The company positioning reflects Canada's unique status as the only jurisdiction where Novo Nordisk's semaglutide patents have expired, creating opportunities for local pharmaceutical manufacturing and supply chain development.

Industry observers note that successful generic launches will depend on manufacturing scale-up, regulatory approval timing, and distribution network establishment across Canadian provinces.

Insurance Coverage Landscape

Current insurance coverage for brand-name semaglutide varies significantly across provincial public plans and private insurers. Some plans require prior authorization or have specific eligibility criteria, while others provide limited or no coverage.

The expert recommendation suggests that lower-cost generic options could enable broader coverage policies, potentially reducing barriers to access. This aligns with general pharmaceutical policy trends favoring generic substitution when therapeutic equivalents become available.

Healthcare policy analysts are watching closely as provincial governments prepare budget assessments for potential generic semaglutide coverage decisions. The medications' high utilization rates make coverage decisions particularly significant for public plan budgets.

Next Steps for Canadians

Patients currently using brand-name semaglutide medications should consult their healthcare providers about generic substitution options once approvals are granted. Pharmacists will typically handle generic substitution automatically unless prescribers specify otherwise.

Those interested in staying informed about generic availability can check our FAQ section for updates on Health Canada approval timelines and provincial coverage decisions.